NAGE insider transaction filings
Niagen Bioscience, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-08. Screen NAGE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cohen Ann — Director | 1 | — | — | 1 |
| Fried Robert N — Chief Executive Officer, Director | 1 | — | — | 1 |
| Jaksch Frank L Jr — Director | 1 | — | — | 1 |
| Lopez Carlos Luis — SVP, General Counsel | 1 | — | — | 1 |
| Ng Wang Yu Gary — Director | 1 | — | — | 1 |
| Pamir Ozan — Chief Financial Officer | 1 | — | — | 1 |
| Patrick Kristin — Director | 1 | — | — | 1 |
| Rubin Steven D — Director | 1 | — | — | 1 |
| Shahbazi Hamed — Director | 1 | — | — | 1 |
| YU Wing Tak Wendy — Director | 1 | — | — | 1 |
Recent Form 4 filings — Niagen Bioscience, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Lopez Carlos Luis — SVP, General Counsel | Grant/award (A): 2,314 @ $2.71 | EDGAR |
| 2026-07-08 | 4 | Pamir Ozan — Chief Financial Officer | Grant/award (A): 4,255 @ $2.71 | EDGAR |
| 2026-07-08 | 4 | Fried Robert N — Chief Executive Officer, Director | Grant/award (A): 1,106 @ $2.71 | EDGAR |
| 2026-06-26 | 4 | Shahbazi Hamed — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Cohen Ann — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Ng Wang Yu Gary — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Patrick Kristin — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | YU Wing Tak Wendy — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Jaksch Frank L Jr — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Rubin Steven D — Director | Grant/award (A): 31,746 (derivative) @ $0 | EDGAR |
| 2026-04-27 | 4 | Fried Robert N — Chief Executive Officer, Director | Option exercise (M): 20,000 @ $2.61 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Lopez Carlos Luis — SVP, General Counsel | Grant/award (A): 41,420 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Pamir Ozan — Chief Financial Officer | Grant/award (A): 62,131 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Fried Robert N — Chief Executive Officer, Director | Grant/award (A): 503,937 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Pamir Ozan — Chief Financial Officer | Purchase (P): 4,464.96 @ $6.81 · Purchase (P): 2,220.44 @ $6.85 | EDGAR |
| 2025-07-03 | 4 | Shahbazi Hamed — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | YU Wing Tak Wendy — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Patrick Kristin — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Ng Wang Yu Gary — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Cohen Ann — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Jaksch Frank L Jr — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Rubin Steven D — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Fried Robert N — Chief Executive Officer, Director | Option exercise (M): 66,667 @ $3.30 · Option exercise (M): 66,667 (derivative) @ $0 | EDGAR |
Recent 8-K events — Niagen Bioscience, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NAGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →